Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Company lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human…More epidermal growth factor receptor 2 negative breast cancer.
REPORT RATINGS
4.8 / 5.0 (188)
Syndax Pharmaceuticals Inc reports have an aggregate usefulness score of 4.8 based on 188 reviews.